Theralink Blog

Latest Blog Entries

This or That: RPPA vs Mass Spectrometry vs ELISA

Previously, we discussed how proteomics is a better measure of the pharmacodynamic effects of target inhibition in drug development. There are a few ways to analyze protein levels and function across patients samples including Mass Spectrometry, ELISA, and our specialty, Reverse Phase Protein Array (RPPA). Today we’ll be giving an overview and comparison of a … Continue reading This or That: RPPA vs Mass Spectrometry vs ELISA

“Mitochondria is the Powerhouse of the Cell”

Mitochondria is the Powerhouse of the Cell. They are also involved in many signaling pathways including cell death, innate immunity, etc.

Into the Thick of It: Next-Generation Proteomics (NGPᵀᴹ)

Theralink is a Next-Generation Proteomics (NGPᵀᴹ) company. What does this even mean???? Well first, let’s bake a cake!   Step 1: Find a recipe Step 2: Gather the ingredients Step 3: Make the batter Step 4: Bake in the Oven   Every one of these steps is necessary to get us our perfect and delicious … Continue reading Into the Thick of It: Next-Generation Proteomics (NGPᵀᴹ)

Theralink Enhanced Vehicles – CAR-T and CAR-NK

Chimeric Antigen Receptor (CAR) therapy is the modification of a patient’s immune cells so that they target cancer cells.  In the case of T-cells and CAR-T therapy, cells are taken from a patient’s blood and modified to include a special receptor (CAR receptor) that binds to a specific protein on the patient’s cancer cells. Scientists … Continue reading Theralink Enhanced Vehicles – CAR-T and CAR-NK

The Big 3: AKT-mTOR, Ras-MAPK, JAK-STAT

Today we will be diving into cross-talk between the Big 3 canonical pathways in cancer research: AKT-mTOR, Ras-MAPK, and JAK-STAT. Up to 70% of all human tumors have upregulated mTORC1 function and several oncogenes and/or tumor suppressors have been linked to mTOR signaling. Consequently, most cancer therapeutic strategies target mTOR signaling by way of AKT … Continue reading The Big 3: AKT-mTOR, Ras-MAPK, JAK-STAT

Into the I/O: A immuno-oncology PD1/PDL1 Case Study

Today let’s look into Immuno-oncology (I/O)- particularly using PD1/PDL1 as a case study! With several companies turning to I/O and immuno-therapy for cancer therapeutics, we offer several upstream and downstream targets of interest for patient stratification! One frequent question from our clients is that: “It’s a cool technology, but how can it benefit my PD-1/PD-L1 … Continue reading Into the I/O: A immuno-oncology PD1/PDL1 Case Study